Design, synthesis, characterization, in silico studies, and in vitro anticancer evaluation of novel 7-methoxyquinolone-substituted triazole hybrids

被引:0
作者
Allito, Lemiye [1 ]
Comert Onder, Ferah [2 ]
Demirel, Ramazan [3 ]
Onder, Alper [4 ]
Ozden, Ozkan [5 ]
Erdogan, Musa [6 ,7 ]
机构
[1] Kafkas Univ, Inst Nat & Appl Sci, Dept Interdisciplinary Biotechnol, Kars, Turkiye
[2] Canakkale Onsekiz Mart Univ, Fac Med, Dept Med Biol, Canakkale, Turkiye
[3] Kafkas Univ, Inst Nat & Appl Sci, Dept Bioengn, Kars, Turkiye
[4] Canakkale Onsekiz Mart Univ, Fac Sci, Dept Chem, Nat Prod & Drug Res Lab, Canakkale, Turkiye
[5] Kafkas Univ, Fac Engn & Architecture, Dept Bioengn, Kars, Turkiye
[6] Kafkas Univ, Fac Engn & Architecture, Dept Food Engn, Kars, Turkiye
[7] Kafkas Univ, Fac Engn & Architecture, Dept Ind Engn, Kars, Turkiye
关键词
Quinolone; click chemistry; anticancer; molecular docking; MD simulation; PROTEIN; SPHK1;
D O I
10.1080/17568919.2025.2533003
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
AimsThe quinolone scaffold is a crucial member of the heterocyclic compound family in modern medicinal chemistry, exhibiting a broad range of biological activities. Since 4-quinolones are known to interact with significant drug targets, and due to the remarkable pharmacological properties of 1,2,3-triazole compounds, a molecular hybridization approach was used to design novel 7-methoxyquinolone-substituted triazole hybrid conjugates (QN1-QN11).Materials and methodsThese hybrid compounds were evaluated to determine their anticancer activities in various breast and colon cancer cell lines, including BT20, MDA-MB-231, MCF7, and HT29. In addition, the apoptotic-like morphological changes in aggressive MDA-MB-231 cells were observed following treatment with the compounds for 48 hours. In silico studies, including molecular docking, molecular dynamics (MD) simulation, and MM/GBSA calculations, were carried out for the synthesized compounds against important cancer drug targets.ResultsThe highly cytotoxic agents QN10 and QN7 were identified with IC50 values of 4.49 +/- 0.68 mu M and 19.05 +/- 1.58 mu M in BT20 and HT29 cell lines, respectively. In addition, the morphologically changes were observed on MDA-MB-231 cells.ConclusionsThese findings show that the synthesized click products are highly cytotoxic agents in cancer cell lines and may be considered as potential candidates for enzyme inhibition.
引用
收藏
页码:1559 / 1573
页数:15
相关论文
共 42 条
[31]  
Onder A., 2024, INT J LIFE SCI BIOTE, V7, P88, DOI [10.38001/ijlsb.1444789, DOI 10.38001/IJLSB.1444789]
[32]   Synthesis of fused 1,2,3-triazoles of Clioquinol via sequential CuAAC and C -H arylation; in vitro anticancer activity, in silico DNA topoisomerase II inhibitory activity and ADMET [J].
Reddy, M. Srinivas ;
Thirukovela, Narasimha Swamy ;
Narsimha, Sirassu ;
Ravinder, M. ;
Nukala, Satheesh Kumar .
JOURNAL OF MOLECULAR STRUCTURE, 2022, 1250
[33]   Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments [J].
Sastry, G. Madhavi ;
Adzhigirey, Matvey ;
Day, Tyler ;
Annabhimoju, Ramakrishna ;
Sherman, Woody .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2013, 27 (03) :221-234
[34]   New quinoline-triazole conjugates: Synthesis, and antiviral properties against SARS-CoV-2 [J].
Seliem, Israa A. ;
Panda, Siva S. ;
Girgis, Adel S. ;
Moatasim, Yassmin ;
Kandeil, Ahmed ;
Mostafa, Ahmed ;
Ali, Mohamed A. ;
Nossier, Eman S. ;
Rasslan, Fatma ;
Srour, Aladdin M. ;
Sakhuja, Rajeev ;
Ibrahim, Tarek S. ;
Abdel-samii, Zakaria K. M. ;
Al-Mahmoudy, Amany M. M. .
BIOORGANIC CHEMISTRY, 2021, 114
[35]   Pharmacophore-guided in-silico discovery of SIRT1 inhibitors for targeted cancer therapy [J].
Sharma, Deepak ;
Muniyan, Rajiniraja .
COMPUTATIONAL BIOLOGY AND CHEMISTRY, 2024, 113
[36]   Recent insight into the biological activities and SAR of quinolone derivatives as multifunctional scaffold [J].
Sharma, Vishal ;
Das, Rina ;
Mehta, Dinesh Kumar ;
Gupta, Sumeet ;
Venugopala, Katharigatta N. ;
Mailavaram, Raghuprasad ;
Nair, Anroop B. ;
Shakya, Ashok K. ;
Deb, Pran Kishore .
BIOORGANIC & MEDICINAL CHEMISTRY, 2022, 59
[37]  
Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
[38]   Ligand-based virtual screening and inductive learning for identification of SIRT1 inhibitors in natural products [J].
Sun, Yunan ;
Zhou, Hui ;
Zhu, Hongmei ;
Leung, Siu-Wai .
SCIENTIFIC REPORTS, 2016, 6
[39]  
Terefinko D, 2024, TOXICOL IN VITRO, V98, DOI 10.1016/j.tiv.2024.105846
[40]   Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies [J].
Wawruszak, Anna ;
Luszczki, Jarogniew ;
Bartuzi, Damian ;
Kalafut, Joanna ;
Okon, Estera ;
Czerwonka, Arkadiusz ;
Stepulak, Andrzej .
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2025, 40 (01)